SG Americas Securities LLC Acquires 158,398 Shares of Amedisys, Inc. (NASDAQ:AMED)

SG Americas Securities LLC boosted its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 413.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 196,713 shares of the health services provider's stock after acquiring an additional 158,398 shares during the quarter. SG Americas Securities LLC owned 0.60% of Amedisys worth $18,985,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Banque Cantonale Vaudoise purchased a new stake in shares of Amedisys in the first quarter valued at about $60,000. Innealta Capital LLC purchased a new position in shares of Amedisys in the 2nd quarter worth approximately $64,000. Covestor Ltd boosted its stake in shares of Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider's stock worth $72,000 after buying an additional 447 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock valued at $104,000 after acquiring an additional 530 shares in the last quarter. Finally, GAM Holding AG purchased a new stake in shares of Amedisys during the second quarter valued at approximately $275,000. Institutional investors own 94.36% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on AMED shares. Deutsche Bank Aktiengesellschaft cut Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price objective on the stock. in a research report on Monday, July 29th. William Blair lowered shares of Amedisys from an "outperform" rating to a "market perform" rating in a research report on Monday, July 1st. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $100.67.

Amedisys Stock Performance

Shares of NASDAQ AMED traded up $0.08 during trading on Friday, reaching $96.12. 370,120 shares of the stock traded hands, compared to its average volume of 334,165. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.16 and a quick ratio of 1.16. The stock has a market capitalization of $3.14 billion, a P/E ratio of -150.19, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. Amedisys, Inc. has a 52-week low of $89.55 and a 52-week high of $98.95. The company has a 50-day moving average of $97.45 and a 200-day moving average of $95.06.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, beating the consensus estimate of $1.22 by $0.10. The business had revenue of $591.19 million for the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. Analysts forecast that Amedisys, Inc. will post 4.66 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.